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Abstract. Drugs like metoclopramide are used in pediatric patients for the treatment of
frequent vomiting or gastrointestinal disorders especially at the age of three. The most common
use is Reglan solution, but its dose should be strictly observed because of low therapeutic index
overdose is easily achieved, manifesting with extrapyramidal side effects.
The purpose of the study is to detect the frequent side-effects of the extrapyramidal
nervous system that are due to the oral overdose of Reglan in the pediatric population.
Materials and methods. This study analyzed all the cases of Metoclopramide toxicity who
took the Reglan solution in an outpatient setting and were then diagnosed and treated in the
Pediatric Service in the Hospital of Elbasan during January 2014 to December 2016 period.
These cases have been treated in the Pediatric Service in Elbasan. After having been diagnosed
with signs of the nervous system from the overdose of Reglan solution they were surveyed in
terms of dose taken, duration of use, age, etc.
Results. The17 cases diagnosed in our service varied in clinical presentation from nuchal
rigidity to whole body contractions and somnolence. Out of these, nine children were younger
than 1 year old, 5 children 1-4 years old, and 3 children were aged 4-8 years. All the children
younger than one received Reglan solution at high doses 3 times 1 coffee spoon (also fivefoldtenfold of the dose) while the therapeutic dose for Reglan solution is 0.1mg / kg in 3-4 doses.
Conclusions. Considering this medication has a low therapeutic index, cautions to prescribe
and administer the right dose are of the upmost importance. As a result, the general practitioner
and the pharmacists should be instructed that children younger than 1 year old should not take
this medication and if need be and there are no other alternatives it should be administered with
drops and not with coffee spoon (2.5 ml) or jam spoon (5 ml).
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Introduction
Metoclopramide is a Dopamine receptor antagonist. Metoclopramide has antiemetic,
antinauseant and gastrokinetic activity. It stimulates motility of the upper
gastrointestinal tract without stimulating gastric, biliary or pancreatic secretions. The
rate of gastric emptying is increased due to increased peristalsis of the jejunum and
duodenum. The tone and amplitude of gastric contractions are increased, with
relaxation of the pyloric sphincter and duodenal bulb. These effects combine to result
in decreased intestinal transit time, making a good anti emetic. The effect of
metoclopramide on motility is not dependent on intact vagal innervation, but it can be
abolished by anticholinergic drugs. Metoclopramide has little, if any, effect on the
motility of the colon or bladder. Metoclopramide also exhibits dopamine antagonist
activity and consequently produces sedation and, rarely, other extrapyramidal
reactions.
It was firstly used by an American physician in 1964 and it has since been used all
over the world. Metoclopramide is one of the 100 most used drugs in the last ten years
in USA. It has also made the list of Essential drugs of World Health Organization
(WHO) [1].
The structural formula is:

Metoclopramide is sold under the trade name Reglan or Primepran and it is widely
used for gastrointestinal disturbances, hiatal hernia, biliary stones, gastritis and gastric
ulcers. This drug is used to control nausea, stomach ache and upper abdominal pain
[2].. In our clinical experience we have witnessed a very high efficacy of this drug in
controlling the vomiting of different causes and makes a great choice in diabetics with
vomiting due to gastroparesis. Metoclopramide is used in surgery to control the postoperative vomiting.
Metoclopramide is also used in pediatric patients to control vomiting due to
gastroenteritis or enteroviral infections. It is essential to administer the correct
dossage due to risky side effects seen with its toxicity. This drug is also used to
control vomiting associated with radiation therapy or intolerance to cytotoxic drug or

used preoperatively to stop the vomiting during surgery and also assists in small
bowel intubation [3]..

Dossage and administration
•
•

Adults 20 years and over: Maximum of 10 mg three times a day.
Children: Treatment of children should commence at the lower dosage of
0.1-0.15 mg/kg three times a day or as a solution 5mg/5ml a clear,
colourless, sterile, preservative-free solution containing metoclopramide
hydrochloride anhydrous used to come with a dropper (Primepran) [4].

Parenteral forms (I.V. or I.M.) are 10 mg/2 ml. This is recomended in patients
with extensive vomiting, after the patient is firstly hydrated with Ringer’s
solution or Sodium Chloride 0.9% [5].

Side effects
Tardive dyskinesia may appear in some patients on long-term therapy or may
appear after drug therapy has been discontinued. The risk appears to be greater in
pediatric patients on high dose therapy. The symptoms are persistent and can often at
times appear to be irreversible. The syndrome is characterized by rhythmical
involuntary movement of the tongue, face, mouth or jaw (e.g. protrusion of tongue,
puffing of cheeks, puckering of mouth, chewing movements). Sometimes these may
be accompanied by involuntary movement of extremities. The frequency and severity
of seizures or extrapyramidal reactions may be increased in epileptic patients given
metoclopramide. Dystonic reactions occur in approximately 1% of patients given
metoclopramide [6]. These occur more often in children and young adults and may
occur after a single dose. Neuroleptic malignant syndrome has been reported when
metoclopramide has been used alone or in combination with neuroleptics.
Metoclopramide elevates prolactin levels. This may be of importance in patients with
previously detected breast cancer, in which the breast cancer is prolactin dependent.
Because of prolactin elevation it presents with disturbances such as galactorrhea,
amenorrhea, gynecomastia and impotence in men. Because of its cholinomimetic
properties and because it decreases intestinal transit time this drug may induce
diarrhea.

The purpose of this study is to evident the extrapyramidal side effects
and other side effects related to Metoclopramide (Reglan) toxicity after oral or
parenteral administration in pediatric population.
Patients and methods

This study analyzed all the cases of Metoclopramide toxicity diagnosed and treated
in the Pediatric Hospital of Elbasan during January 2014 to December 2016 period.
The cases were then classified regarding the epidemiologic criteria, the dosage
administered to the patient, the time the patient was on the drug, the coexistence of
other pathologies and socio-demographic variables like: age, residency.

Results
There were 17 cases in total diagnosed in the Pediatric Hospital of Elbasan. Their
clinical symptoms varied from neck rigidity to whole body contractions and
somnolence. Some of the children had “facial mask” or facial spasms. Patients aged
older than 3 years old could not talk and they exhibit uncontrollable movements of the
extremities and they fell whenever they tried to walk.
9 of the 17 children were younger than 1 year of age, 5 children were 1-4 years of
age and 3 were 4-8 years old.

Graph 1: Children classified by age group.
All the children younger than 1 year old were administered Reglan solution 5-10
times (3 times 1 coffee spoon) the allowed dose of 0.1mg/kg 3 times a day.
Regarding their place of residence: 11 children were located in rural areas while
only 6 were located in urban areas.

Graph 2: Place of residence of children who were intoxicated with
Metoclopramide.
Regarding the pathology the children first came for in the clinic for which they
took Metoclopramide: 6 were diagnosed as Enteroviral infection, 7 cases of
Gastroenteritis and 4 of Gastroesophageal reflux (GERD).

Graph 3: Divided by the pathology the children first came for in the clinic for
which they took Metoclopramide

In our study we analyzed the cases of Metoclopramide (Reglan) toxicity
considering the timeline of emerging side effects. In children younger than 1 year of
age the first signs of intoxication started during the second day (after the first 24h) of
taking the medication. Six out of nine of these cases had a severe clinical
manifestation with extrapyramidal signs because of taking the medication in doses of
4-5 ml.

Discussion
Side effects from metoclopramide (Reglan) toxicity are fairly often in the clinical
practice compared to other medications. The most cases are reported in pediatric
population. This is illustrated on Graphic 1 where more than 60 % of the cases
included in this study are 0-1 years of age. Infants are poisoned with this medication,
receiving a dose greater than the maximal daily dose of 0.3 mg/kg (0.1 – 0.15 mg/kg
taken 2-3 times a day) [7]. A 7 kg child should not be administered more than 10-15
drops per day (0.7 ml 2-3 times a day). In this study we found out that many children
have received the medication 2-3 times per day up to 4-5 ml, making it an overdose.
In this situation the children were presented to the Emergency Room with the
extrapyramidal symptoms described above [8]. This mistake occurs due to a
miscommunication between the physician and pharmacist, the latter one being
responsible a lot of times for selling medications without prescription or misreads the
correct dosage of the medication.
The risk is increased because in our country Metoclopramide that is sold under the
trade name Reglan lacks a dropper. A few years ago Primeran solution was widely
available in the drug market in Albania. It had a dropper that helped avoiding
mistakes in dossing administration.
In this study we found that most of the cases were from rural centers. This not only
shows the problems and the shortcoming of specialized doctors in these zones but also
the lack of medical knowledge in the population. In two cases after the children,
respectively 4 and 7 years of age, were still vomiting after taking Reglan, the medical
personnel administered Primepran (I.M.) too. Another added risk factor we came
through was the non-administration of Ringer or Glucose solution to treat the
dehydration after taking Reglan. Certain authors emphasize the contraindication of
Metoclopramide in infants (<1 year old) because of the side effects [9] [10].
In recent years even though there is an increase in other anti-emetics like
Domperidone or Ranitidine to treat the acutely ill patients, Metoclopramide still
remains the most preferred due to best efficacy in clinical setting even though the
literature suggests that there are no differences in efficacy between Domperidone and
Metoclopramide. Domperidone is suggested to be used more due to its safer profile
[11].
Ondansetron, a serotonin 5HT-3 antagonist, FDA approved for children older than
1 month of age (earlier than any of the other medications discussed above). Scientific
evidence support the use of Ondansetron in children that present with vomiting [12].
It is the only antiemetic for which there are randomized, controlled trials that support
its use. A meta-analysis from DeCamp et al., all the children who were administered
Ondansetron were less predisposed to have ongoing vomiting, need for I.V. fluids or

hospitalization. In Europe Ondansetron is available in 16 countries under the trade
name Setofilm in 4 mg and 8 mg doses [13] [14].
Patient and parents experience these sudden and rapidly accelerated symptoms very
dramatically making it very hard to get an anamnesis.
One other study from LC Low and K M Goel observed 15 children with
metoclopramide (MaxoIon) poisoning. One of the 5 children accidentally poisoned
developed slight extrapyramidal signs. All 10 children who experienced
extrapyramidal side effects while being treated with metoclopramide had received a
dose greater than that recommended by the manufacturer of 0,5 mg/kg per day [15].
Dystonic reactions are likely to occur if the recommended dose is exceeded, but
individual susceptibility to metoclopramide and the cumulative effect of repeated
doses of the drug may also be important. Similar reasons were identified in our study.

Conclusions
Side effects from Reglan solution (Metoclopramide) are common in pediatric
population and happen due to mistakes in dosing. Considering this medication has a
low therapeutic index, cautions to prescribe and administer the right dose are of the
upmost importance. As a result, the general practitioner and the pharmacists should be
instructed that children younger than 1 year old should not take this medication and if
need be and there are no other alternatives it should be administered with drops and
not with coffee spoon (2.5 ml) or jam spoon (5 ml).
A healthy professional interaction between the physician, the pharmacist and the
nursing staff is very important in order to elude the mistakes in the future. Medical
personnel should be advised to not administer Metoclopramide P.O. or I.M. before
starting fluids in order to hydrate the patient when dehydration is present. After the
electrolyte balances are controlled lowering the risk of side effects, the patient can be
administered Metoclopramide to control the vomiting.
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